Idorsia Ltd (IDRSF)
| Market Cap | 1.26B +344.8% |
| Revenue (ttm) | 278.18M +96.1% |
| Net Income | -140.86M |
| EPS | -0.66 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 7,376 |
| Open | 4.320 |
| Previous Close | 4.380 |
| Day's Range | 4.320 - 4.320 |
| 52-Week Range | 1.000 - 5.820 |
| Beta | 1.67 |
| RSI | 50.82 |
| Earnings Date | Apr 28, 2026 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t... [Read more]
Financial Performance
In 2025, Idorsia's revenue was 220.58 million, an increase of 96.06% compared to the previous year's 112.51 million. Losses were -111.70 million, -57.65% less than in 2024.
Financial numbers in CHF Financial StatementsNews
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
Allschwil, Switzerland – May 6, 2026 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Boa...
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps Co-promotion of QUVIVIQ is bei...
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Allschwil, Switzerland – April 10, 2026 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meetin...
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Allschwil, Switzerland – April 9, 2026 Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Developmen...
Idorsia announces the nomination of three candidates for election to the Board of Directors
Allschwil, Switzerland – March 24, 2026 Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of ...
Idorsia announces management change
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026 Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti wi...
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Idorsia (IDRSF) to CHF 5 from CHF 6 and keeps a Buy rating on the shares. The firm cites reduced forward visibility
Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink
Allschwil, Switzerland – March 10, 2026 Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridor...
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
Allschwil, Switzerland – January 30, 2026 Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORL...
Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd...
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conferenc...
Nature Communications reports promising effect of Idorsia's lucerastat on kidney function in Fabry disease
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, a...
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
Allschwil, Switzerland – January 6, 2026 Idorsia Ltd (SIX: IDIA) announces the initiation of a Phase 2 proof-of-concept trial evaluating IDOR-1117-2520 for participants with moderate-to-severe psorias...
Idorsia's daridorexant in women during menopausal transition age with insomnia
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal tra...
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces that Health Canada has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertensio...
Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product' category
Allschwil, Switzerland – December 9, 2025 Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien Bridges Award in the category of “...
Idorsia upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux upgraded Idorsia (IDRSF) to Buy from Hold with a CHF 4.50 price target The firm sees a better investment case post the company’s restructuring.
Idorsia's aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
Allschwil, Switzerland – November 10, 2025 Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Journal of Hypertension titled “Effects ...
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
Allschwil, Switzerland – November 05, 2025 Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia's endothelin receptor antagonist, will be p...
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia's tra...
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUB...
Idorsia launches an offering of registered shares – to fund the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUB...
Global expansion of Idorsia's QUVIVIQ continues as Simcere launches in China
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) in China. QUVIVIQ, Idor...